Collegium Pharmaceutical, Inc. Earnings Recaps
Q1 2026
May 9, 2026
Collegium Pharmaceutical’s stock rose 3.5% after the quarter, driven by stronger-than-expected growth in JORNAY prescriptions and accelerated revenue from the ADHD portfolio, supported by the imminent AZSTARYS acquisition.
Key takeaways
- JORNAY prescriptions grew 14% year-over-year, generating $38.9 million in net revenue, up 36% year-over-year.
- Pain portfolio net revenues increased 4% year-over-year to $154.6 million, underpinning steady cash flow.
- Total net product revenues rose 9%, with adjusted EBITDA also up 9% year-over-year.
- Generated $57.1 million in cash from operations, ending the quarter with a strong cash position of $421.8 million, up $35 million sequentially.
- Proposed acquisition of AZSTARYS is progressing, expected to close in Q2, and anticipated to enhance growth, margin expansion, and portfolio longevity through 2037.